{"title":"质子泵抑制剂与肾病:事实还是虚构?","authors":"Matthew Ryan Weir","doi":"10.1159/000538755","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nProton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).\n\n\nSUMMARY\nThe available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, dose response relationship, replacement of findings, cessation of exposure, specificity of the association and consistency with other knowledge, one can only conclude that there is no consistent relationship between PPI use and the development of CKD, or its progression.\n\n\nKEY MESSAGES\nThere is insufficient evidence to link PPI exposure with the development or progression of CKD.","PeriodicalId":7570,"journal":{"name":"American Journal of Nephrology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?\",\"authors\":\"Matthew Ryan Weir\",\"doi\":\"10.1159/000538755\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\nProton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).\\n\\n\\nSUMMARY\\nThe available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, dose response relationship, replacement of findings, cessation of exposure, specificity of the association and consistency with other knowledge, one can only conclude that there is no consistent relationship between PPI use and the development of CKD, or its progression.\\n\\n\\nKEY MESSAGES\\nThere is insufficient evidence to link PPI exposure with the development or progression of CKD.\",\"PeriodicalId\":7570,\"journal\":{\"name\":\"American Journal of Nephrology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000538755\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538755","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景质子泵抑制剂(PPI)是治疗消化不良和胃食管反流的常用处方药。摘要 已发表的文献未能证实 PPI 与慢性肾脏病(CKD)的发生有关。安慰剂对照试验表明,安慰剂和 PPI 的 CKD 发生率没有差异。如果按照布拉德福德-希尔(Bradford Hill)的观点(包括时间关系、关联强度、剂量反应关系、研究结果的替代性、接触的停止、关联的特异性以及与其他知识的一致性)来审查数据,只能得出这样的结论:PPI 的使用与 CKD 的发生或发展之间不存在一致的关系。
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
BACKGROUND
Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).
SUMMARY
The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, dose response relationship, replacement of findings, cessation of exposure, specificity of the association and consistency with other knowledge, one can only conclude that there is no consistent relationship between PPI use and the development of CKD, or its progression.
KEY MESSAGES
There is insufficient evidence to link PPI exposure with the development or progression of CKD.
期刊介绍:
The ''American Journal of Nephrology'' is a peer-reviewed journal that focuses on timely topics in both basic science and clinical research. Papers are divided into several sections, including: